Bioprocessing

Biomanufacturers should do the math: calculate whether small, parallelized product streams can exceed the sum of their parts, thanks to lower cleaning costs and other advantages of single-use technology.

Lack of pathogenicity and other advantages over Escherichia coli make Bacillus subtilis an attractive host expression system, says GenScript, especially if secretory capacity is enhanced.

Biopharmaceutical production depends on buffers. Making sure the right buffer solutions are available, in the right place on the manufacturing line, at the right time, and in the right quantity, is a considerable challenge.

Study results indicate that a previously uncharacterized 54 amino acid microprotein called PIGBOS sits on the outer mitochondrial membrane and plays a key role in modulating the unfolded protein response, or UPR, which mitigates a form of cellular stress. Dysregulation of UPR is thought to underpin a range of diseases including Alzheimer's disease and other neurodegenerative disorders.

Sponsored content brought to you by Mammalian cell expression systems are the dominant tool today for the production of complex biotherapeutic proteins. Different CHO hosts are used routinely to develop such biologics and are combined...

A deep-learning based computational approach called unified representation, or UniRep, has been used to distill the fundamental features of a protein from the protein’s unlabeled amino acid sequences. UniRep promises to accelerate the design of synthetic proteins that possess desirable functions in varied biomanufacturing applications.

Danaher has agreed to sell three of its life sciences tools businesses to Sartorius Stedim Biotech for approximately $750 million cash—a deal that according to Danaher was prompted by its planned $21.4 billion acquisition of GE Life Sciences’ Biopharma business.

GE Healthcare (GEHC) and Ireland’s National Institute of Bioprocessing Research and Training (NIBRT) are partnering to deliver educational training programs focused on biopharmaceutical and cell therapy development and manufacturing, building on a two-year-old collaboration.

In this study MilliporeSigma's goal was to modify a well-defined cell line development system to generate high performing recombinants in a time- and resource-efficient manner.

In this MilliporeSigma sponsored content, we explores they'r mini-pool approach as fast track process for small biotechs who are on a very challenging timeline. It enables us to start process development and production of early material before cell line development is completed.